Corcept Shares Plunge After FDA Corrected Letter Shows Prior Warnings Against Submission
Shares of Corcept Therapeutics tumbled after the U.S. Food and Drug Administration issued a corrected complete response letter stating the agency had warned the company on multiple occasions not to file its application for relacorilant. The letter highlighted lack of separation from placebo in the main trial and raised significant liver safety conc…